Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Revenues Slide, Losses Widen in Q1 of FY05

NEW YORK, July 30 (GenomeWeb News) - Accelrys yesterday reported a sharp drop in revenues and a widening loss for the first quarter of its fiscal year 2005, ended June 30.

 

The company had $14.2 million in revenues, down from $19.1 million during the same quarter last year. Accelrys attributed this drop in part to a change in revenue recognition for annual and multi-year licenses and smaller consulting and consortia revenues. The change in revenue recognition "will continue to dramatically affect reported revenue through the next three to four quarters," according to a company statement.

 

Research and development costs stayed flat, at $4.1 million, compared to $4.6 million during the same quarter a year ago.

 

The net loss for the quarter totaled $6.2 million, or $.25 per share, up from $3.8 million, or $.16 per share, during the year-ago quarter. This included a $1.1 million loss from the discontinued Pharmacopeia Drug Discovery unit.

 

As of June 30, Accelrys, which changed its name from Pharmacopeia in May, had $83.8 million in cash, restricted cash, cash equivalents, and marketable securities.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.